Numerator
Number of female deaths due to breast cancer (ICD-10 code C50)
Methodology
At the National level this Indicator uses Age-Adjustment Groups:
- Race/Ethnicity: < 1, 1-4, 5-14, 15-24, 25-34, 35-44, 45-54, 55-64, 65-74, 75-84, 85+
- Sex: < 1, 1-4, 5-14, 15-24, 25-34, 35-44, 45-54, 55-64, 65-74, 75-84, 85+
- Marital Status: 25-34, 35-44, 45-54, 55-64, 65-74, 75-84, 85+
- Metro Location: < 1, 1-4, 5-14, 15-24, 25-34, 35-44, 45-54, 55-64, 65-74, 75-84, 85+
- Country of Birth: < 5, 5-17, 18-24, 25-34, 35-44, 45-54, 55-64, 65-74, 75+
- Total: < 1, 1-4, 5-14, 15-24, 25-34, 35-44, 45-54, 55-64, 65-74, 75-84, 85+
Death due to malignant neoplasm of the female breast (ICD-10 code C50).
FOR SINGLE DATA YEARS: Rates are calculated based on the April 1 census counts for the censal years (e.g., 2000) and July 1 estimates from the Vintage matching the data year for the postcensal period. For example, for rates of data year 2004, the 2004 population estimates from Vintage 2004 are used as denominator.
FOR MULTIPLE DATA YEARS: Rates are calculated based on sum of data year populations from the Vintage matching the data years. For example, for rates of data years 2004-2006 combined, the sum of 2004 population from Vintage 2004, 2005 population from Vintage 2005, and 2006 population from Vintage 2006 are used as denominator.
Interventions
One-on-one education is provided in person or by telephone to encourage individuals to be screened for cancer.
Some interventions seek to increase cancer screening by reducing out-of-pocket costs.
Many barriers can make it difficult for people to seek screening for cancer.
Reminders include letters, postcards, or phone calls to alert clients that it is time for their cancer screening.
Small media include videos and printed materials such as letters, brochures, and newsletters.
Provider-oriented interventions aim to increase recommendation and delivery of screening for cancers by health care providers.
The USPSTF recommends that women whose family history is associated with an increased risk for deleterious mutations in BRCA1 or BRCA2 genes be referred for genetic counseling and evaluation for BRCA testing.
The USPSTF recommends biennial screening mammography for women aged 50 to 74 years.
The USPSTF recommends that clinicians discuss chemoprevention with women at high risk for breast cancer and at low risk for adverse effects of chemoprevention.